<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="pmc-domain-id">1609</journal-id><journal-id journal-id-type="pmc-domain">bmjo</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10255039</article-id><article-id pub-id-type="pmcid-ver">PMC10255039.1</article-id><article-id pub-id-type="pmcaid">10255039</article-id><article-id pub-id-type="pmcaiid">10255039</article-id><article-id pub-id-type="pmid">37258082</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2022-068729</article-id><article-id pub-id-type="publisher-id">bmjopen-2022-068729</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Addiction</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject><subject>1681</subject></subj-group><series-title>Protocol</series-title></article-categories><title-group><article-title>Comparative effectiveness of urine drug screening strategies alongside opioid agonist treatment in British Columbia, Canada: a population-based observational study protocol</article-title></title-group><contrib-group><contrib id="author-101734348" contrib-type="author"><name name-style="western"><surname>Guerra-Alejos</surname><given-names initials="BC">B Carolina</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib id="author-101734349" contrib-type="author"><name name-style="western"><surname>Kurz</surname><given-names initials="M">Megan</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib id="author-101734350" contrib-type="author"><name name-style="western"><surname>Min</surname><given-names initials="JE">Jeong Eun</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib id="author-101734351" contrib-type="author"><name name-style="western"><surname>Dale</surname><given-names initials="LM">Laura M</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib id="author-101734352" contrib-type="author"><name name-style="western"><surname>Piske</surname><given-names initials="M">Micah</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib id="author-93947340" contrib-type="author"><name name-style="western"><surname>Bach</surname><given-names initials="P">Paxton</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib id="author-37407905" contrib-type="author"><name name-style="western"><surname>Bruneau</surname><given-names initials="J">Julie</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib id="author-21509138" contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2375-5006</contrib-id><name name-style="western"><surname>Gustafson</surname><given-names initials="P">Paul</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib id="author-101734356" contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="XJ">X Joan</given-names></name><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib id="author-73058688" contrib-type="author"><name name-style="western"><surname>Kampman</surname><given-names initials="K">Kyle</given-names></name><xref rid="aff9" ref-type="aff">9</xref></contrib><contrib id="author-63853237" contrib-type="author"><name name-style="western"><surname>Korthuis</surname><given-names initials="PT">P Todd</given-names></name><xref rid="aff10" ref-type="aff">10</xref><xref rid="aff11" ref-type="aff">11</xref></contrib><contrib id="author-101734359" contrib-type="author"><name name-style="western"><surname>Loughin</surname><given-names initials="T">Tom</given-names></name><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib id="author-37525357" contrib-type="author"><name name-style="western"><surname>Maclure</surname><given-names initials="M">Malcolm</given-names></name><xref rid="aff12" ref-type="aff">12</xref></contrib><contrib id="author-26043514" contrib-type="author"><name name-style="western"><surname>Platt</surname><given-names initials="RW">Robert W</given-names></name><xref rid="aff13" ref-type="aff">13</xref></contrib><contrib id="author-58452360" contrib-type="author"><name name-style="western"><surname>Siebert</surname><given-names initials="U">U</given-names></name><xref rid="aff14" ref-type="aff">14</xref><xref rid="aff15" ref-type="aff">15</xref></contrib><contrib id="author-66761050" contrib-type="author"><name name-style="western"><surname>Soc&#237;as</surname><given-names initials="ME">M Eugenia</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib id="author-74359529" contrib-type="author"><name name-style="western"><surname>Wood</surname><given-names initials="E">Evan</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib id="author-32269906" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2513-3718</contrib-id><name name-style="western"><surname>Nosyk</surname><given-names initials="B">Bohdan</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Centre for Health Evaluation and Outcome Sciences</institution>, <addr-line content-type="city">Vancouver</addr-line>, <addr-line content-type="state">British Columbia</addr-line>, <country>Canada</country></aff><aff id="aff2"><label>2</label><institution content-type="department">Faculty of Health Sciences</institution>, <institution specific-use="Ringgold_1763">Simon Fraser University</institution>, <addr-line content-type="city">Burnaby</addr-line>, <addr-line content-type="state">British Columbia</addr-line>, <country>Canada</country></aff><aff id="aff3"><label>3</label><institution content-type="department">Faculty of Medicine</institution>, <institution specific-use="Ringgold_8166">The University of British Columbia</institution>, <addr-line content-type="city">Vancouver</addr-line>, <addr-line content-type="state">British Columbia</addr-line>, <country>Canada</country></aff><aff id="aff4"><label>4</label><institution specific-use="Ringgold_558158">British Columbia Centre on Substance Use</institution>, <addr-line content-type="city">Vancouver</addr-line>, <addr-line content-type="state">British Columbia</addr-line>, <country>Canada</country></aff><aff id="aff5"><label>5</label><institution content-type="department">Department of Family Medicine and Emergency Medicine</institution>, <institution specific-use="Ringgold_5622">University of Montreal</institution>, <addr-line content-type="city">Montreal</addr-line>, <addr-line content-type="state">Qu&#233;bec</addr-line>, <country>Canada</country></aff><aff id="aff6"><label>6</label><institution content-type="department">Research Center</institution>, <institution>Centre hospitalier de l'Universit&#233; de Montr&#233;al</institution>, <addr-line content-type="city">Montr&#233;al</addr-line>, <addr-line content-type="state">Quebec</addr-line>, <country>Canada</country></aff><aff id="aff7"><label>7</label><institution content-type="department">Department of Statistics</institution>, <institution specific-use="Ringgold_8166">The University of British Columbia</institution>, <addr-line content-type="city">Vancouver</addr-line>, <addr-line content-type="state">British Columbia</addr-line>, <country>Canada</country></aff><aff id="aff8"><label>8</label><institution content-type="department">Department of Statistics and Actuarial Science</institution>, <institution specific-use="Ringgold_1763">Simon Fraser University</institution>, <addr-line content-type="city">Burnaby</addr-line>, <addr-line content-type="state">British Columbia</addr-line>, <country>Canada</country></aff><aff id="aff9"><label>9</label><institution content-type="department">Department of Psychiatry</institution>, <institution specific-use="Ringgold_6572">University of Pennsylvania</institution>, <addr-line content-type="city">Philadelphia</addr-line>, <addr-line content-type="state">Pennsylvania</addr-line>, <country>USA</country></aff><aff id="aff10"><label>10</label><institution content-type="department">School of Public Health</institution>, <institution specific-use="Ringgold_143856">OHSU-PSU</institution>, <addr-line content-type="city">Portland</addr-line>, <addr-line content-type="state">Oregon</addr-line>, <country>USA</country></aff><aff id="aff11"><label>11</label><institution content-type="department">Section of Addiction Medicine</institution>, <institution specific-use="Ringgold_6684">Oregon Health &amp; Science University</institution>, <addr-line content-type="city">Portland</addr-line>, <addr-line content-type="state">Oregon</addr-line>, <country>USA</country></aff><aff id="aff12"><label>12</label><institution content-type="department">Department of Anesthesiology, Pharmacology and Therapeutics</institution>, <institution specific-use="Ringgold_8166">The University of British Columbia</institution>, <addr-line content-type="city">Vancouver</addr-line>, <addr-line content-type="state">British Columbia</addr-line>, <country>Canada</country></aff><aff id="aff13"><label>13</label><institution content-type="department">Departments of Epidemiology, Biostatistics, and Occupational Health and of Pediatrics</institution>, <institution specific-use="Ringgold_5620">McGill University</institution>, <addr-line content-type="city">Montreal</addr-line>, <addr-line content-type="state">Qu&#233;bec</addr-line>, <country>Canada</country></aff><aff id="aff14"><label>14</label><institution content-type="department">Center for Health Decision Science, Department of Health Policy and Management</institution>, <institution specific-use="Ringgold_1857">Harvard University T H Chan School of Public Health</institution>, <addr-line content-type="city">Boston</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff><aff id="aff15"><label>15</label><institution content-type="department">Department of Public Health, Health Services Research and Health Technology Assessment</institution>, <institution specific-use="Ringgold_550270">Private University of Health Sciences Medical Informatics and Technology Hall/Tyrol Institute for Health Information Systems</institution>, <addr-line content-type="city">Hall in Tirol</addr-line>, <country>Austria</country></aff><author-notes><corresp><label>Correspondence to</label> Dr Bohdan Nosyk; <email>bnosyk@sfu.ca</email></corresp></author-notes><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>31</day><month>5</month><year>2023</year></pub-date><volume>13</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">435194</issue-id><elocation-id>e068729</elocation-id><history><date date-type="received"><day>29</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>26</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>10</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-06-12 05:25:11.000"><day>12</day><month>06</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement><copyright-year>2023</copyright-year><ali:free_to_read/><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2023-05-31">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bmjopen-2022-068729.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="bmjopen-2022-068729.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="reviewers-comments-pdf" xlink:href="bmjopen-2022-068729.reviewer_comments.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="draft-revisions-pdf" xlink:href="bmjopen-2022-068729.draft_revisions.pdf"/><abstract><sec><title>Introduction</title><p>Urine drug tests (UDTs) are commonly used for monitoring opioid agonist treatment (OAT) responses, supporting the clinical decision for take-home doses and monitoring potential diversion. However, there is limited evidence supporting the utility of mandatory UDTs&#8212;particularly the impact of UDT frequency on OAT retention. Real-world evidence can inform patient-centred approaches to OAT and improve current strategies to address the ongoing opioid public health emergency. Our objective is to determine the safety and comparative effectiveness of alternative UDT monitoring strategies as observed in clinical practice among OAT clients in British Columbia, Canada from 2010 to 2020.</p></sec><sec><title>Methods and analysis</title><p>We propose a population-level retrospective cohort study of all individuals 18 years of age or older who initiated OAT from 1 January 2010 to 17 March 2020. The study will draw on eight linked health administrative databases from British Columbia. Our primary outcomes include OAT discontinuation and all-cause mortality. To determine the effectiveness of the intervention, we will emulate a &#8216;per-protocol&#8217; target trial using a clone censoring approach to compare fixed and dynamic UDT monitoring strategies. A range of sensitivity analyses will be executed to determine the robustness of our results.</p></sec><sec><title>Ethics and dissemination</title><p>The protocol, cohort creation and analysis plan have been classified and approved as a quality improvement initiative by Providence Health Care Research Ethics Board and the Simon Fraser University Office of Research Ethics. Results will be disseminated to local advocacy groups and decision-makers, national and international clinical guideline developers, presented at international conferences and published in peer-reviewed journals electronically and in print.</p></sec></abstract><kwd-group><kwd>substance misuse</kwd><kwd>statistics &amp; research methods</kwd><kwd>epidemiology</kwd><kwd>primary care</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="funding-1"><funding-source><institution-wrap><institution>National Institutes on Drug Abuse</institution></institution-wrap></funding-source><award-id>R01 DA-050629</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title></caption><list list-type="bullet"><list-item><p>British Columbia&#8217;s single-payer healthcare system constitutes an ideal setting for direct comparisons of medical care and monitoring strategies at the population level and within key subgroups.</p></list-item><list-item><p>A per-protocol analysis, implemented with inverse probability censorship weights and clone-censor-weight approaches, will provide a direct comparison of static and dynamic monitoring strategies administered as observed in clinical practice throughout the province of British Columbia, Canada.</p></list-item><list-item><p>Potential uncontrolled confounding and other threats to validity will be assessed via a range of sensitivity analyses.</p></list-item></list></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p>Urine drug testing (UDT) is commonly used alongside opioid agonist treatment (OAT) to assess medication adherence and ongoing illegal drug use as a proxy for monitoring treatment response. UDTs can assess progress by confirming intake of prescribed OAT, validating self-reported substance use and supporting clinical decisions for take-home doses.<xref rid="R1" ref-type="bibr">1 2</xref> UDTs, thus, provide one element of the ongoing clinical assessment of treatment response, which also includes ongoing evaluation of psychosocial well-being, quality of life, progress towards substance use goals, and improvement in health and social functioning.<xref rid="R3" ref-type="bibr">3</xref> An additional rationale for UDT is to provide a means of monitoring the possibility of diversion, and potentially serve as a deterrent against diversion.<xref rid="R4" ref-type="bibr">4&#8211;6</xref> British Columbia&#8217;s (BC) approach to OAT management embeds patient-centred care where a positive UDT result for opioids and other substances should not discontinue treatment.<xref rid="R1" ref-type="bibr">1</xref> Although provincial,<xref rid="R1" ref-type="bibr">1 4</xref> national<xref rid="R3" ref-type="bibr">3 5</xref> and international<xref rid="R7" ref-type="bibr">7&#8211;16</xref> guidelines recommend a non-punitive approach to positive UDT results, several qualitative and observational studies have documented that take-home doses are postponed during initiation or curtailed as a result of illicit drug use as clinical stability has not been attained.<xref rid="R1" ref-type="bibr">1 3 5 7 8 11 14 17</xref> Other responses from consistently positive UDT results during OAT include counselling, referral to a specialist and/or OAT discontinuation if risks to the client or public outweigh benefits.<xref rid="R1" ref-type="bibr">1 8 17 18</xref></p><p>In BC, UDTs can be administered in a laboratory setting, in a primary care office or within treatment facilities via point of care immunoassay testing kits.<xref rid="R1" ref-type="bibr">1</xref> The sensitivity of laboratory-based tests in detecting illicit opioid use ranges from 98% to 100%, with a specificity of 50%&#8211;91%,<xref rid="R19" ref-type="bibr">19</xref> while point of care tests feature a sensitivity of 80%&#8211;98%,<xref rid="R20" ref-type="bibr">20</xref> and a reported positive predictive value of 86% for opiates.<xref rid="R21" ref-type="bibr">21</xref> Another study reported a 79.4% sensitivity for opiates, 65.4% for benzodiazepines, 33.3% for buprenorphine, 37.5% for cocaine, 78.3% for amphetamines and 92.5% for oxycodone/oxymorphone.<xref rid="R22" ref-type="bibr">22</xref> Test sensitivity can decrease with longer detection times of substances and can otherwise vary according to personal patterns of use.<xref rid="R1" ref-type="bibr">1</xref> While point of care test kits carry obvious advantages for clients, they feature cross-reactivity that could affect test results.<xref rid="R1" ref-type="bibr">1 23 24</xref> Further, these tests typically cannot discern substances within a particular drug class.<xref rid="R23" ref-type="bibr">23 25</xref> The increasing toxicity and adulteration of the illegal drug supply in BC, Canada and elsewhere thus further challenges interpretation of UDT results.<xref rid="R26" ref-type="bibr">26&#8211;28</xref></p><p>Additional guidance on the use of UDTs for OAT clients in BC was issued in 2021,<xref rid="R1" ref-type="bibr">1</xref> updating guidelines published in 2017.<xref rid="R4" ref-type="bibr">4</xref> The updated guidance recommends testing frequency should be determined by the client&#8217;s treatment response and specifies a maximum of 26 UDTs per year, or biweekly screening. During induction, UDTs for both buprenorphine/naloxone and methadone clients are recommended monthly or when clinically indicated. After completing induction, UDTs are recommended based on prescriber judgement. Given methadone&#8217;s pharmacological properties and longer half-life, previous UDT guidelines recommended more frequent testing as a means of monitoring diversion and patient response.<xref rid="R29" ref-type="bibr">29</xref> While induction for buprenorphine/naloxone lasts 1&#8211;2 weeks, methadone induction can last weeks to months.<xref rid="R4" ref-type="bibr">4</xref> Clients receiving take-home doses are recommended less frequent UDTs: 6&#8211;8 random tests per year for methadone clients and 2&#8211;4 for buprenorphine/naloxone clients. Although not described as contingency management, previous and current BC guidelines use UDTs to assess substance use abstinence and reward clients with take-home doses.<xref rid="R4" ref-type="bibr">4</xref> However, recent evidence has shown that contingency management does not demonstrate added value for OAT retention, abstinence or adherence.<xref rid="R4" ref-type="bibr">4 30 31</xref></p><p>BC&#8217;s guidelines are more stringent than others internationally in recommending testing with a periodic frequency as opposed to occasional testing. While international guidelines on UDT frequency vary widely, guidelines typically provide distinct recommendations for the induction phase, postinduction (ie, reaching a dose that allows clients to be adequately supported in their daily lives without withdrawal symptoms or cravings<xref rid="R6" ref-type="bibr">6 32</xref>) and for clients receiving take-home doses. Most of these guidelines acknowledge that buprenorphine/naloxone stabilisation is achieved earlier (as little as 3&#8211;5&#8201;days) in comparison to methadone, where more than 5 weeks are often needed to attain stabilisation.<xref rid="R17" ref-type="bibr">17</xref> We summarise the recommendations from a convenience sample of three Canadian provincial and ten national guidelines on UDT protocols in North America, Australia and Europe (<xref rid="T1" ref-type="table">table 1</xref>). National guidelines from the USA, Canada and France recommend at least weekly UDT during OAT induction.<xref rid="R5" ref-type="bibr">5 8&#8211;10 16 17</xref> Guidelines in the UK, Australia and New Zealand call for frequent UDTs during induction without providing a specific frequency.<xref rid="R11" ref-type="bibr">11 12 15 18</xref> From the thirteen clinical guidelines we assessed, eight recommended prescribers&#8217; judgement to determine UDT frequency during induction.<xref rid="R1" ref-type="bibr">1 11&#8211;13 15&#8211;18</xref></p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Urine drug test (UDT) frequency guideline comparison for opioid agonist treatment (OAT)</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="top" rowspan="2" colspan="1">Guideline</td><td align="left" valign="top" rowspan="2" colspan="1">Minimum/ maximum tests</td><td align="left" valign="top" colspan="3" rowspan="1">Recommended UDT frequency for OAT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Induction, titration and/or stabilisation</td><td align="left" valign="top" rowspan="1" colspan="1">Postinduction</td><td align="left" valign="top" rowspan="1" colspan="1">Take-home doses</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">BC, CAN, (2021)<xref rid="R1" ref-type="bibr">1</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Max. 26 at POC per patient/year</td><td align="left" valign="top" rowspan="1" colspan="1">BNX: Monthly or frequently when clinically indicated. MET: Monthly. Frequently as required and when clinically indicated. If UDT is &lt;monthly, patient safety can be increased with DWI.</td><td align="left" valign="top" rowspan="1" colspan="1">BNX and MET: When clinically indicated.</td><td align="left" valign="top" rowspan="1" colspan="1">BNX: Scheduled when clinically indicated; &#8805; 2&#8211;4 random tests yearly, frequency increased if there&#8217;s safety concerns. MET: Scheduled when clinically indicated with &#8805;6&#8211;8 random tests yearly, frequency increased if there&#8217;s safety concerns.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRISM, CAN, (2018)*<xref rid="R5" ref-type="bibr">5</xref></td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" rowspan="1" colspan="1">Varies per province. BNX: At least 1 UDT before initiation; After each patient appointment; Random. MET: At least 1 UDT before initiation; 1&#8211;2 per week to every 1&#8211;4&#8201;months.</td><td align="left" valign="top" rowspan="1" colspan="1">Varies per province. BNX: Frequency based on clinical judgement; Random. MET: Weekly, monthly, or every 3&#8201;months; Random.</td><td align="left" valign="top" rowspan="1" colspan="1">Varies per province. BNX: Until clinical stability is achieved. MET: Combination of time since treatment initiation and repeated negative UDTs.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CAMH, CAN, (2021)<xref rid="R3" ref-type="bibr">3</xref></td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" rowspan="1" colspan="1">Weekly while stabilising.</td><td align="left" valign="top" rowspan="1" colspan="1">Every 1&#8211;3&#8201;months; Random.</td><td align="left" valign="top" rowspan="1" colspan="1">BNX: &#8805;1&#8201;month (induction and dose escalation). MET: Same as BNX; More frequent to confirm abstinence or take-home doses; scheduled and random.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SAMHSA, USA (2021)<xref rid="R10" ref-type="bibr">10 17</xref> (2012)<xref rid="R9" ref-type="bibr">9</xref></td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" colspan="2" rowspan="1">&#8805;1 before initiation; at providers discretion: frequency consistent with office visits, reduced as UDTs are frequently negative, and random as visits become less frequent.</td><td align="left" valign="top" rowspan="1" colspan="1">Tailored to each patient.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ASAM, USA, (2017)<xref rid="R8" ref-type="bibr">8</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Min. 8 per patient/year</td><td align="left" valign="top" rowspan="1" colspan="1">Weekly and on a random schedule; more frequent.</td><td align="left" valign="top" rowspan="1" colspan="1">At least monthly and on a random schedule; less frequent.</td><td align="left" valign="top" rowspan="1" colspan="1">Tailored to each patient.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CSAM, California, USA, (2019)<xref rid="R7" ref-type="bibr">7</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Follows ASAM.&#8805;1 monthly</td><td align="left" valign="top" rowspan="1" colspan="1">Follows ASAM. POC tests are optional. Before treatment initiation; Random and at least once a month.</td><td align="left" valign="top" rowspan="1" colspan="1">Follows ASAM. POC tests are optional. BUP: N/A MET: At least once every 90 days and tailored to each patient.</td><td align="left" valign="top" rowspan="1" colspan="1">Lab testing required for state specified &#8216;regular&#8217; take-home criteria changes.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UK, 2017<xref rid="R11" ref-type="bibr">11</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Min. 2 per patient/year</td><td align="left" valign="top" rowspan="1" colspan="1">Random but frequent in initial phases; Tailored to each patient.</td><td align="left" valign="top" rowspan="1" colspan="1">Random; at least twice a year.</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NICE CKS, UK, revised 2022<xref rid="R12" ref-type="bibr">12</xref></td><td align="left" valign="top" rowspan="1" colspan="1">2&#8211;4 per year (stability)</td><td align="left" valign="top" rowspan="1" colspan="1">Random but frequent; based on clinical judgement; tailored to each patient.</td><td align="left" valign="top" rowspan="1" colspan="1">Random; 2&#8211;4 times a year.</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Australia, 2014<xref rid="R18" ref-type="bibr">18</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Max. 36 per patient/year</td><td align="left" valign="top" rowspan="1" colspan="1">Frequent during dose initiation and stabilisation; random; based on clinical judgement.</td><td align="left" valign="top" rowspan="1" colspan="1">Random; based on clinical judgement.</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">New South Wales, AUS, 2018<xref rid="R13" ref-type="bibr">13</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Max. 36 per patient/year</td><td align="left" valign="top" colspan="2" rowspan="1">Based on treatment needs (high, medium, low). Minimum clinical and medical review (1&#8211;6&#8201;months). UDTs mimic medical and clinical review frequency.</td><td align="left" valign="top" rowspan="1" colspan="1">Regular UDTs (risk assessment for take-home doses)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Western Australia, AUS, 2014<xref rid="R14" ref-type="bibr">14</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Max. 36 per patient/year</td><td align="left" valign="top" rowspan="1" colspan="1">BUP: N/A MET: Random.</td><td align="left" valign="top" rowspan="1" colspan="1">Based on clinical judgement; Only if results are likely to be important.</td><td align="left" valign="top" rowspan="1" colspan="1">Regular UDTs (risk assessment for take-home doses)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">New Zealand, 2014<xref rid="R15" ref-type="bibr">15</xref></td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" colspan="2" rowspan="1">Each service is responsible for the frequency of UDTs. Random testing is recommended.</td><td align="left" valign="top" rowspan="1" colspan="1">UDTs must be positive for prescribed OAT.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">France, 2004<xref rid="R16" ref-type="bibr">16</xref></td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" rowspan="1" colspan="1">Compulsory before starting MET; As clinically required; UDTs related to medication allowance: 28 days for BUP, 14 days for MET</td><td align="left" valign="top" rowspan="1" colspan="1">BUP and MET: As clinically required and agreed by patient.</td><td align="left" valign="top" rowspan="1" colspan="1">Tailored to each patient.</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><p>*BC guidelines in CRISM are excluded from the information contained in the table.</p></fn><fn id="T1_FN2"><p>ASAM, American Society of Addiction Medicine; BC, British Columbia; BNX, buprenorphine/naloxone; BUP, buprenorphine (without naloxone); CAMH, Centre for Addiction and Mental Health; CKS, Clinical Knowledge Summaries; CRISM, Canadian Research Initiative on Substance Misuse; CSAM, California Society of Addiction Medicine; DWI, daily witnessed ingestion; MET, methadone; N/A, not available; NICE, National Institute for Health and Care Excellence; POC, point of care; SAMHSA, Substance Abuse and Mental Health Services Administration.</p></fn></table-wrap-foot></table-wrap><p>Following successful induction and stabilisation, guidelines follow a frequency from monthly<xref rid="R8" ref-type="bibr">8 13 16</xref> to random<xref rid="R15" ref-type="bibr">15 18</xref> with most guidelines recommending a minimum number of tests per year, ranging from 2<xref rid="R11" ref-type="bibr">11&#8211;13</xref> to 12.<xref rid="R3" ref-type="bibr">3 5 7 13</xref> Otherwise, 10 of 13 guidelines we assessed recommended prescriber judgement postinduction.<xref rid="R1" ref-type="bibr">1 5 7 11 13&#8211;18</xref> For clients receiving take-home doses, Canadian guidelines specify testing frequency based on the type of OAT a client receives ranging from monthly testing to twice a year.<xref rid="R1" ref-type="bibr">1 3 5</xref> Nine guidelines specify that clinical decision regarding take-home doses is necessary to dictate UDT frequency.<xref rid="R1" ref-type="bibr">1 3 5 7 8 13 14 16 17</xref> Six of 13 clinical guidelines recommended more frequent UDTs for clients on methadone compared with buprenorphine/naloxone, including national and provincial guidelines in Canada. This was true both postinduction and for those receiving take-home doses.<xref rid="R1" ref-type="bibr">1 3 5</xref></p><p>The lack of concordance in clinical guidelines on the frequency of UDT alongside OAT is a reflection of the paucity of evidence supporting this practice. Evidence referenced in UDT guidelines was derived from randomised controlled trial study protocols and systematic reviews reporting inconclusive results or no significant differences for the effects of UDT on OAT retention.<xref rid="R33" ref-type="bibr">33&#8211;37</xref> While one recent study from a single clinical practice in Massachusetts demonstrated the utility of UDT in validating self-reported illicit drug use,<xref rid="R38" ref-type="bibr">38</xref> the systematic review by Dupouy <italic toggle="yes">et al</italic><xref rid="R34" ref-type="bibr">34</xref> concluded that UDTs had no or inconclusive evidence of effectiveness in improving substance use disorder treatment outcomes or retention. The systematic review included eight studies concluding that evidence related to UDTs was insufficient to inform clinical judgement and of poor quality.<xref rid="R34" ref-type="bibr">34</xref> The testing frequency, study setting and type of assay were inconsistent among the studies included in the systematic review, ultimately leading to inconclusive results for the implementation of UDTs in the treatment of substance use disorder. A separate systematic review by McEachern <italic toggle="yes">et al</italic>, concluded that, compared with scheduled frequency, random UDTs can provide more information on the use of other substances in addition to OAT, though the review noted challenges in rural regions with limited laboratory testing resources.<xref rid="R35" ref-type="bibr">35</xref> These reviews highlight the inadequacy of the underlying evidence base in supporting informed guidance on UDT frequency among people on OAT. Current evidence and guidelines thus rely heavily on clinical judgement, which can be prone to bias<xref rid="R35" ref-type="bibr">35</xref> and may reflect clinical convention rather than evidence-based practice.<xref rid="R39" ref-type="bibr">39</xref></p><p>These clinical conventions are influenced by the risk of diversion, though evidence to support this concern are also sparse. The limited evidence on the association between UDT frequency and opioid diversion is focused on chronic pain settings rather than OUD.<xref rid="R40" ref-type="bibr">40&#8211;42</xref> BC Coroner&#8217;s reports indicate that opioid-related deaths with diverted OAT are relatively rare; of 333 unintended opioid-related deaths recorded between 2009 and 2013, methadone had been prescribed within 60 days in over 30% of fatalities related to prescription opioids, however, just 14 people (17%) did not have an active prescription.<xref rid="R43" ref-type="bibr">43</xref> Out of 1854 overdose deaths in 2016&#8211;2017, 615 had drug toxicology testing completed where only 31 tested positive for methadone (5%) and none for buprenorphine/naloxone.<xref rid="R44" ref-type="bibr">44</xref> Though relaxations in UDT monitoring frequency and take-home dosing occurred during the COVID-19 pandemic in the USA, deaths involving methadone declined before and after March 2020 while monthly overdose deaths not involving methadone increased by 78 deaths per month before March 2020, by 1078 deaths in March 2020 and by 69 deaths per month after March 2020.<xref rid="R45" ref-type="bibr">45</xref></p><p>Otherwise, while full-agonist treatments such as methadone and slow release oral morphine are pharmaceuticals that have a higher risk of overdose among the opioid-naive,<xref rid="R1" ref-type="bibr">1</xref> OAT medications produce muted feelings of euphoria,<xref rid="R46" ref-type="bibr">46</xref> and thus may be less desirable than other illicit options. Studies from harm reduction sites, inpatient and community-based clinics in BC, Massachusetts and Michigan, respectively, have supported this notion,<xref rid="R47" ref-type="bibr">47&#8211;49</xref> and the introduction of fentanyl and illegal benzodiazepines<xref rid="R50" ref-type="bibr">50</xref> to the drug supply in North America have further shifted the pattern of consumption as well as increased the tolerance level for opioids.<xref rid="R51" ref-type="bibr">51&#8211;54</xref> Recent studies from two ongoing community-recruited cohorts of people who use drugs in Vancouver, BC, have shown that, due to the unpredictability of the illegal drug supply, some clients diverted OAT as a means to reduce fentanyl-related risks given its lower street cost than fentanyl.<xref rid="R55" ref-type="bibr">55 56</xref> Qualitative studies of users of diverted OAT have indicated use as a signal of interest in receiving treatment for opioid use.<xref rid="R57" ref-type="bibr">57</xref></p><p>Qualitative studies assessing clients&#8217; perspectives on UDT have suggested that random drug testing, or pill counts, may be systemic barriers to daily life.<xref rid="R58" ref-type="bibr">58 59</xref> UDTs and callbacks for clinic pill counts, along with limited access to take-home doses and daily witnessed ingestion requirements, have all been cited as challenges to stable retention in treatment.<xref rid="R58" ref-type="bibr">58 60</xref> Patient dissatisfaction has been expressed in settings with inflexible clinic protocols, including shorter follow-up intervals following positive UDTs.<xref rid="R60" ref-type="bibr">60</xref> Travel times and accessibility of laboratory services are noted barriers to treatment in BC in particular.<xref rid="R61" ref-type="bibr">61</xref> Changing medication dosing based on UDT results can be perceived as paternalistic among individuals on OAT.<xref rid="R62" ref-type="bibr">62</xref> As such, despite guidelines emphasising patient-oriented care and advising that UDTs should not be used punitively, qualitative evidence demonstrates UDTs may foster distrust, damage the rapport between client and provider, and compromise treatment outcomes.<xref rid="R63" ref-type="bibr">63</xref> Furthermore, as provider discretion is often recommended in determining frequency of testing, it is unclear whether client characteristics such as housing, employment, ethnicity or other factors are considered in decisions on the frequency of UDT monitoring and other aspects of clinical management of individuals on OAT.<xref rid="R64" ref-type="bibr">64</xref></p><p>In summary, despite widespread recommendations for and use of UDT alongside OAT, there is sparse evidence that it represents an effective tool in helping to stabilise and prolong retention among individuals in treatment. Furthermore, qualitative evidence suggests it may serve as a barrier to treatment and compromise client&#8211;physician rapport. As such, we aimed to determine the safety and comparative effectiveness of alternative UDT monitoring strategies as observed in clinical practice among buprenorphine/naloxone and methadone clients in BC, Canada: 2010&#8211;2021. We note that while monitoring the risk of diversion is one of the uses of UDTs, this phenomenon is not directly observable in health administrative data. The question of diversion represents a distinct and testable hypothesis which lies outside the scope of this study. We will focus on the individual-level effects of UDT on OAT, which should be the primary consideration in clinical decision-making in this context.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Study design</title><p>We propose a population-level retrospective study based on a linkage of eight provincial health administrative databases from BC, Canada to satisfy study objectives. The BC PharmaNet database<xref rid="R65" ref-type="bibr">65</xref> (capturing medication dispensations) will be used to identify all OAT dispensations for directly observed and take-home doses. As BC residents are required to enrol in the provincial single-payer health insurance plan, these records are comprehensive, excluding only dispensations to individuals in federal corrections facilities and during hospitalisation. These data are linked with records from the Discharge Abstract Database<xref rid="R66" ref-type="bibr">66</xref> (records of hospitalisations), Medical Services Plan<xref rid="R67" ref-type="bibr">67</xref> (MSP; physician billing records), BC Vital Statistics<xref rid="R68" ref-type="bibr">68</xref> (capturing deaths and their underlying cause), BC Provincial Corrections<xref rid="R69" ref-type="bibr">69</xref> (records of entry into incarcerations and releases to community), Perinatal Care Database<xref rid="R70" ref-type="bibr">70</xref> capturing maternal/infant care and outcomes), National Ambulatory Care Reporting System Database<xref rid="R71" ref-type="bibr">71</xref> (capturing ED visits) and BC Social Development and Poverty Reduction database<xref rid="R72" ref-type="bibr">72</xref> (capturing social assistance receipt). The databases are deterministically linked using a unique, individual-level deidentified personal health number.<xref rid="R73" ref-type="bibr">73</xref> A summary of the data extraction timeline from the various linked databases can be found in <xref rid="F1" ref-type="fig">figure 1</xref>.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>Databases, data extraction time frame and study period. Health administrative databases from British Columbia (BC), Canada. Medical Services Plan (MSP), Discharge Abstract Database (DAD), BC Vital Statistics (BCVS) and PharmaNet (PNET) available from 1 January 1996 to 31 August 2021. BC Corrections and Social Development and Poverty Reduction (SDPR) available from 1 January 2010 to 31 December 2020. National Ambulatory Care Reporting System (NACRS) available from 1 April 2012 to 31 August 2021. Perinatal Services BC (PSBC) available from 1 August 2000 to 31 March 2021. Study period begins on January 2010, ending on 17 March 2020. UDT, urine drug test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bmjopen-2022-068729f01.jpg"/></fig><p>All individuals 18 years of age or older who initiate an OAT regimen between 1 January 2010 to 17 March 2020 will be included, providing as much complete follow-up as allowed by the linked datasets prior to the disruptions in care prompted by the COVID-19 pandemic. Women with known pregnancy at OAT initiation will be excluded from the analysis, as care plans including urine drug screening frequency may differ during pregnancy from general care for OUD. Otherwise, UDTs are typically billed through MSP on a fee-for-service basis, however, some clients receive care in community health centres and other settings in which physicians bill the alternative payment plan.<xref rid="R74" ref-type="bibr">74</xref> As a result, individuals with no MSP records will be censored within fourteen days of initial OAT dispensation. We will further censor individuals with a gap larger than 4&#8201;weeks between MSP records for OAT assessments and refills to account for switching care to a prescriber working under the alternative payment plan. The key elements of our proposed study design are summarised in <xref rid="T2" ref-type="table">table 2</xref>. Our planned study start is April 2023 and will be completed within a 6-month period.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Key design components of the emulated target trial on UDT monitoring frequency</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Component</td><td align="left" valign="bottom" rowspan="1" colspan="1">Theoretical target trial</td><td align="left" valign="bottom" rowspan="1" colspan="1">Emulating using observational data</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Eligibility criteria</td><td align="left" valign="top" rowspan="1" colspan="1">Individuals initiating OAT with no prior OAT dispensations.</td><td align="left" valign="top" rowspan="1" colspan="1">Incident new-user design: People initiating OAT in BC between 1 January 2001 and 17 March 2020 with no history of OAT, dating back to 1 January 1996.<break/>Prevalent new-user design: people initiating OAT with no history of OAT in the past 30 days.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment strategies</td><td align="left" valign="top" rowspan="1" colspan="1">Individuals are randomly assigned to a UDT strategy of none, weekly, monthly, quarterly or biannual screening.</td><td align="left" valign="top" rowspan="1" colspan="1">Treatment strategies are assigned according to the frequency of UDT requisition records.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary Outcomes</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Treatment discontinuation</p></list-item><list-item><p>All-cause mortality.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Treatment discontinuation: interruptions in prescribed doses lasting at least 5&#8201;days for methadone and at least 6&#8201;days for buprenorphine/naloxone.<break/>All-cause mortality: the date of death was identified within the provincial Vital Statistics database.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Follow-up</td><td align="left" valign="top" rowspan="1" colspan="1">From treatment initiation until the earliest of treatment discontinuation, death, lost to follow-up or end of study follow-up</td><td align="left" valign="top" rowspan="1" colspan="1">From treatment initiation until the earliest of treatment discontinuation, death, pregnancy, taper initiation or end of study period (17 March 2020).</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Causal contrasts</td><td align="left" valign="top" rowspan="1" colspan="1">Intention-to-treat and per-protocol effect</td><td align="left" valign="top" rowspan="1" colspan="1">Per-protocol effect only.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Analysis plan</td><td align="left" valign="top" rowspan="1" colspan="1">Intention-to-treat analysis: Cox model estimating the relative risk of discontinuation across strategies.<break/>Per-protocol analysis: individuals are censored when they deviate from the initial treatment strategies. Per-protocol effect estimation requires adjustments for prebaseline and postbaseline prognostic factors associated with adherence to the strategies of interest.</td><td align="left" valign="top" rowspan="1" colspan="1">As treatment strategies are not observed at baseline we follow a clone-censor-weight approach.</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1"><p>BC, British Columbia; OAT, opioid agonist treatment; UDT, urine drug test.</p></fn></table-wrap-foot></table-wrap><p>Time zero will be defined as the date of first OAT dispensation in community. We will execute both incident user and prevalent new user study designs to ensure the clinical experience of both initial entrants and those accessing treatment in successive attempts are captured. The former design will exclude clients with any prior OAT dispensations (to be confirmed with data reaching back to 1 January 1996), while for the latter we will apply a 30-day wash-out period (ie, no OAT dispensations received in the prior 30 days) and otherwise adjust for past OAT exposure. All analyses will be stratified according to the form of medication received at OAT initiation. OAT episodes initiated using slow-release oral morphine or injectable forms of OAT&#8212;first introduced in BC as treatment options in 2017<xref rid="R4" ref-type="bibr">4</xref> and 2016,<xref rid="R75" ref-type="bibr">75</xref> respectively, will be excluded given the relatively limited experience and observational data available for these treatments. Some episodes may be initiated with multiple forms of OAT prescribed concurrently; these episodes will also be excluded.</p><p>Study follow-up will begin at treatment initiation and extends to the earliest of treatment discontinuation, death, pregnancy, taper initiation (date of second consecutive weekly dosage decrease), medication switch or end of study follow-up (17 March 2020). Observations will be updated on a weekly basis from the date of initiation of each episode until treatment discontinuation or censorship.</p></sec><sec id="s2-2"><title>Key measures</title><p>The primary exposure proposed is the UDT monitoring strategy used during OAT. Specifically, we aim to compare UDT monitoring strategies which differ with respect to the frequency UDT billing records are observed. We will consider both static and dynamic strategies to account for differences in guideline recommendations during and after induction, as well as during receipt of take-home doses. We will initially consider five static monitoring strategies: no UDTs, and weekly, monthly, quarterly and biannual UDTs. The dynamic strategy allows for changes to UDT strategy after completing the induction phase of treatment. We will consider no UDTs, weekly and monthly prior to induction completion, and no UDTs, weekly, monthly, quarterly after induction, amounting to 12 possible strategies. We will have a 1-week allowance for UDT billing for the weekly strategy, 2-week allowance for the monthly strategy and a 6-week allowance for both the quarterly and biannual strategies. We chose these intervals to capture the range of recommendations on testing frequency, both in BC and internationally. These intervals are predetermined; however, the analysis will allow us to evaluate these strategies based on their observed frequency in real-world clinical settings.</p><p>Our primary outcomes proposed include OAT discontinuation, drug-related hospitalisation and all-cause mortality. Discontinuation will be defined as a break in prescribed doses lasting at least 5&#8201;days for methadone and at least 6&#8201;days for buprenorphine/naloxone, consistent with clinical guidelines on dose reversion following discontinuation.<xref rid="R4" ref-type="bibr">4</xref> All-cause mortality is observed via linkage to vital statistics records.</p></sec><sec id="s2-3"><title>Statistical analysis</title><p>Our proposed analysis is informed by analogous studies executed by the HIV-CAUSAL collaboration, comparing both static and dynamic CD4-monitoring strategies in people living with HIV.<xref rid="R76" ref-type="bibr">76&#8211;78</xref> To emulate a &#8216;per-protocol&#8217; target trial where each eligible individual is randomly assigned to 1 of the 5 static monitoring strategies (or 1 of the 12 dynamic monitoring strategies), we will create an expanded dataset by making five exact replicates of each individual (one per strategy). When an individual&#8217;s data are no longer consistent with a given strategy, we will artificially censor the corresponding replicate at that time. Replicates will be censored at the point of deviation from protocol; that is, when they are monitored sooner than indicated by a given strategy or when they are not monitored soon enough. The primary exposure will thus be fixed over time and capture the true observed frequency of UDTs.</p><sec id="s2-3-1"><title>Inverse probability of censorship weight estimation</title><p>Inverse probability of censorship weights (IPCW) will be constructed to account for the potential that the censoring strategy employed may introduce time-dependent selection bias. As treatment strategies are not observed at baseline, we propose to employ the &#8216;clone-censor-weight&#8217; approach,<xref rid="R79" ref-type="bibr">79 80</xref> which entails weighting each replicate by the inverse of the probability of having one&#8217;s own observed monitoring history at each time step.<xref rid="R81" ref-type="bibr">81 82</xref></p><p>The weights will be defined as:</p><p>
<disp-formula id="E1"><mml:math id="eqn1" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>S</mml:mi><mml:mi>W</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:munderover><mml:mo movablelimits="false">&#8719;</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:munderover><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>C</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>Z</mml:mi><mml:mo>,</mml:mo><mml:mi>G</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>L</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>C</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>Z</mml:mi><mml:mo>,</mml:mo><mml:mi>G</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula>
</p><p>where N(t) is the indicator of artificial censoring by changing the strategy at time t, C(t) an indicator of censoring by loss to follow-up at time t, and L(t) is any time varying factors at time t, A is the strategy assigned at baseline, Z is the vector of baseline covariates and G is an indicator for whether the baseline eligibility criteria are met.</p><p>Assumptions for IPCW to correct for informative censoring include: (1) no unmeasured confounders; (2) correct model specification (model to derive the weights); (3) positivity, entailing that the probability of deviating from protocol is non-zero at all follow-up times and for each client; (4) consistency, which entails the observed outcome under a treatment strategy is identical to what would have been observed had we assigned patients to the treatment strategy and (5) the censorship weights can remove imbalance between treatment strategies through standardised differences defined for each main factor as the weighted difference between groups divided by the weighted pooled SD. A variable with a standardised difference below 10% is considered balanced.</p><p>For the primary and secondary outcomes, we will present HRs obtained from a marginal structural Cox model with censorship weights and robust variance to control for repeated weekly observations and, in the prevalent new user design, repeated episodes within individuals.<xref rid="R83" ref-type="bibr">83</xref> The partial likelihood of the weighted time dependent Cox model will be:</p><p>
<disp-formula id="E2"><mml:math id="eqn2" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>P</mml:mi><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>&#946;</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munderover><mml:mo movablelimits="false">&#8719;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:munderover><mml:munderover><mml:mo movablelimits="false">&#8719;</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>&#946;</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:munderover><mml:mo movablelimits="false">&#8721;</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>&#946;</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula>
</p></sec><sec id="s2-3-2"><title>Comparing fixed monitoring strategies</title><p>We will first impose a fixed monitoring strategy featuring set UDT monitoring intervals that do not change throughout the OAT episode, from initiation to discontinuation or censorship. For example, considering a weekly strategy, UDT is required every 1&#8211;14&#8201;days due to the allowance period; otherwise individuals are censored for deviation from the monitoring strategy. This form of censoring is informative, similarly to the informative censoring introduced with the replicates, and IPCW will be implemented to correct for the informative censoring.</p></sec><sec id="s2-3-3"><title>Comparing dynamic monitoring strategies</title><p>We also propose to construct dynamic strategies that allow change over time during the treatment episode, pending sufficient sample sizes to achieve model convergence. This approach will allow for a change in UDT frequency once induction is completed, defined as the first 2-week period of with no change in the average daily dosage.<xref rid="R84" ref-type="bibr">84</xref> This strategy is proposed based on several guidelines recommending a change in UDT frequency after completing induction. An illustration of the counting process and censoring rules for this and other study designs is provided in <xref rid="F2" ref-type="fig">figure 2</xref>. This will result in 12 different levels of the primary exposure, which is expressed as a bivariate pair of strategies preinduction and postinduction. If the strategy change is not as defined, such as a strategy change before completing induction or another change after induction, it will be censored. Similar to the fixed strategy approach, the informative censoring introduced in this scenario requires correction through IPCW.</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p>Proposed dynamic strategy compared with delayed 1-month static strategy. (A) represents six hypothetical individuals&#8217; contributions and trajectories in the dynamic strategy scenario, where a change in strategy is allowed after completing induction. (B) displays the same six hypothetical individuals for the static strategies under the 1-month start scenario. Person A in (A) switches from weekly to monthly monitoring after reaching the postinduction phase, and therefore, is not censored; however, under the 1-month static scenario this individual is censored after week 7 as the UDT requisition on week 5 implied the individual was still following the weekly strategy. Note that person D, F are excluded in (B) as they have no UDTs within the first month and are thus not eligible for the 1-month and 3-month start analyses. In (A), person E and B are both censored prior to the postinduction phase, as (B) shows they had switched to the monthly UDT strategy. However, in (B) they are not as the 1-month start allows for the strategies to reset, and therefore, they are included in the 1-month strategy until they discontinue OAT. Person C remained uncensored in both (A, B) as they were consistently on the 1-month UDT strategy under both scenarios. OAT, opioid agonist treatment; UDT, urine drug test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bmjopen-2022-068729f02.jpg"/></fig></sec><sec id="s2-3-4"><title>Covariate selection</title><p>While the assumption of no uncontrolled confounding cannot be verified in observational settings, we will adjust for all potential confounders available within our linked database,<xref rid="R85" ref-type="bibr">85</xref> such as recent drug-related hospitalisation or ED (<xref rid="F3" ref-type="fig">figure 3</xref>). We previously identified these covariates by conducting a systematic literature review of articles published up to 2 September 2019 regarding factors associated with OAT retention among.<xref rid="R86" ref-type="bibr">86</xref> We propose to augment this listing with additional variables available in our linked administrative data which we hypothesise to influence both UDT monitoring frequency and OAT retention. These additional measures will include variables to capture the physician&#8211;client relationship that we hypothesise will impact adherence to the assigned strategy and other time varying covariates (<xref rid="F4" ref-type="fig">figure 4</xref>). We will construct variables on the proportion of other non-OAT billing records or prescriptions from the same physician (polychotomous), and the clients&#8217; relationship with general practitioners (polychotomous)<xref rid="R87" ref-type="bibr">87</xref> based on the amount and proportion of physician billing records. We hypothesise that UDTs prior to episode initiation may influence censoring of the &#8216;no UDT&#8217; strategy in particular. We; therefore, propose to include a covariate to capture whether an initial UDT was provided within 7&#8201;days of treatment initiation (dichotomous). All time-varying covariates will be updated weekly, pending achievement of model convergence. Results from UDTs will not be available in the administrative data, therefore, we will be unable to observe whether changes in strategies are due to positive or negative test results. As BC clinical guidelines recommend that UDTs not be used punitively, results should not impact changes in testing schedules and our methodology will still provide recommendations based on the assumption the results of UDTs will not be used punitively.</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><p>Covariates derived from the administrative databases for previous studies. ED, emergency department; OAT, opioid agonist treatment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bmjopen-2022-068729f03.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4</label><caption><p>Directed acyclic graph detailing the exposure and outcome. Z represents any baseline confounders which are fix in time and which may impact an individual&#8217;s adherence to their assigned UDT strategy, such as a non-opioid substance use disorders, which may change the frequency a physician orders UDTs throughout the treatment course. A<sub>0</sub> and A<sub>t</sub> represent adherence to the UDT strategies assigned at baseline (no UDT, weekly, biweekly, monthly, quarterly biannually). P<sub>0</sub> and P<sub>1</sub> represent time-varying physician-level variables such as physician&#8211;client relationship that may impact exposure and other time-varying variables but not the outcome. L<sub>0</sub> and L<sub>1</sub> represent time-varying covariates that may impact adherence to the UDT strategy assigned at baseline and retention such as carries received and medication dosage. U is any unmeasured confounders that may impact time-varying confounders, such as an individuals&#8217; ongoing illicit drug usage which may impact a physician&#8217;s decision to approve carries or change the UDT strategy. We do not observe the unmeasured confounders and plan to control their impact via the physician-level variables. UDT, urine drug test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bmjopen-2022-068729f04.jpg"/></fig></sec><sec id="s2-3-5"><title>Subgroup and sensitivity analysis</title><p>We will execute sensitivity analyses by restricting the cohort and study timeline, as well as altering the definitions of both the artificial censuring rules used to construct the primary exposure and the primary outcome (<xref rid="T3" ref-type="table">table 3</xref>). For similar reasons to proposing the dynamic strategies we propose to restrict the cohort to those retained for at least 4 weeks and 12 weeks as well as those who receive take-home doses postinduction and who had received at least one UDT within these time frames (implying exclusion of the &#8216;no UDT&#8217; strategy in this sensitivity analysis). We will execute the same static monitoring strategy, using the time from their last recorded UDT (ie, occurring before the 12-week time point) for censorship assignment to avoid misclassification, while also adding a covariate indicating their monitoring strategy in weeks 0&#8211;12 to account for potential confounding by indication. This will provide an additional robustness check for the proposed dynamic monitoring strategies using the simpler fixed monitoring strategy analytical setup. To prevent immortal time bias, all inferences on this selected subgroup will be qualified accordingly, to ensure no comparisons are made with individuals not reaching the temporal threshold. Applicable results will be presented in tornado diagrams centred on the baseline relative risk from each analytical strategy. Any post hoc additions to or deviations from this protocol will be identified as such in final reports.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Proposed subgroup and sensitivity analyses</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Proposed sensitivity analysis</td><td align="left" valign="bottom" rowspan="1" colspan="1">Rationale</td></tr></thead><tbody><tr><td align="left" valign="top" colspan="2" rowspan="1">1. Sample restriction</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Additional stratification by OAT history</td><td align="left" valign="top" rowspan="1" colspan="1">To account for individuals that may have more strict or lenient UDT strategies due to OAT experience.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Allowing for medication switching*</td><td align="left" valign="top" rowspan="1" colspan="1">To account for individuals receiving BUP who switch to MET if withdrawal symptoms are not alleviated,<xref rid="R39" ref-type="bibr">39</xref> and to account for individuals switching from MET to BUP or other medication.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Extend wash-out period to 90 days</td><td align="left" valign="top" rowspan="1" colspan="1">To assess the sensitivity of gap times between episodes and account for any changes that may be impacted by more recent OAT experience.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Inclusion criteria requiring past mental health condition</td><td align="left" valign="top" rowspan="1" colspan="1">Individuals with mental health conditions may have different care requirements and results may be impacted based on differing care.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Inclusion criteria requiring past non-opioid substance use disorder diagnosis</td><td align="left" valign="top" rowspan="1" colspan="1">Individuals with prior indications of non-opioid substance use disorder may require different monitoring strategies based on care requirements.</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">2. Timeline restriction</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Introduction of fentanyl in the illegal drug supply (2014)</td><td align="left" valign="top" rowspan="1" colspan="1">The change in the illegal drug supply may have altered both treatment retention (outcome), and the extent to which prescribers ordered UDT screens (exposure).</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">3. Exposure classification</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stratified analyses on UDT modality&#8212;point-of-care and lab-based</td><td align="left" valign="top" rowspan="1" colspan="1">Point-of-care UDTs, introduced in 2009 with lab-based requiring individuals to go to a lab after the physician makes a requisition. Reclassifying the exposure can measure if there is a difference on retention for the type of UDT. This approach has nine different static strategies instead of five.<break/>Further stratification by immunoassay type is not possible as immunoassay information is not available for point-of-care testing.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Increasing the allowance time between UDTs for the strategies</td><td align="left" valign="top" rowspan="1" colspan="1">Ensure the results are not sensitive to the defined allowance time for each strategy.</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">4. Model specification</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Starting study from 3 months into treatment</td><td align="left" valign="top" rowspan="1" colspan="1">UDT monitoring strategies may change over time in practice. Starting the study from a predefined time point can account for the differences in treatment strategies.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Starting study at first take-home dose postinduction</td><td align="left" valign="top" rowspan="1" colspan="1">UDT monitoring strategies are different for individuals who receive take-home dosing. Guidelines suggest take-home dosing should be available only when a client is stabilised and UDT guidelines for monitoring are stricter during induction than for those receiving take-homes.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dynamic strategies to account for adaptive clinical practice</td><td align="left" valign="top" rowspan="1" colspan="1">Static strategies may not fit for clinical practice when treatment strategies change over time after stabilisation or when take-home doses are received.</td></tr></tbody></table><table-wrap-foot><fn id="T3_FN1"><p>*Allowing continuous OAT episodes to account for switching from buprenorphine/naloxone to methadone, or from methadone to buprenorphine/naloxone as indicated by BC guidelines. If prescribed doses (during switching) do not follow BC.</p></fn><fn id="T3_FN2"><p>BC, British Columbia; BUP, buprenorphine; MET, methadone; OAT, opioid agonist treatment; UDT, urine drug test.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s2-4"><title>Patient and public involvement</title><p>While no patients were explicitly involved in the design of this study, its conception was influenced by prior engagement with local advocacy organisations of people who use drugs and people who have accessed OAT.<xref rid="R61" ref-type="bibr">61</xref> Qualitative feedback on this and other related objectives outlined in the parent grant R01DA050629 were used to prioritise this analysis given the potential impact on client engagement. Findings will be shared with local advocacy groups following completion of the analysis.</p></sec></sec><sec id="s3"><title>Ethics and dissemination</title><p>Databases are available to the research team by BC Ministries of Health and Mental Health and Addiction as part of the response to the provincial opioid overdose public health emergency. This study is classified as a quality improvement initiative. Providence Health Care Research Institute and the Simon Fraser University Office of Research Ethics determined the analysis met criteria for exemption per Article 2.5 of the 2018 Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans.<xref rid="R88" ref-type="bibr">88</xref> This study will follow international guidelines for study conduct and reporting, including Strengthening the Reporting of Observational Studies in Epidemiology guidelines.<xref rid="R89" ref-type="bibr">89</xref> We will otherwise administer the &#8216;Risk of Bias in Non-Randomised Studies-of Interventions&#8217; tool to a multidisciplinary scientific advisory committee for ex post evaluation. Results will be disseminated to local advocacy groups and decision-makers, national and international clinical guideline developers, presented at international conferences and published in peer-reviewed journals electronically and in print. This study will generate robust evidence on how UDT frequency compares in real-world practice for OAT retention over the long term in the interest of improving retention in these essential<xref rid="R90" ref-type="bibr">90</xref> and life-saving<xref rid="R91" ref-type="bibr">91</xref> medications.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="d64e415" position="float" orientation="portrait"><caption><title>Reviewer comments</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bmjopen-2022-068729.reviewer_comments.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material content-type="local-data" id="d64e416" position="float" orientation="portrait"><caption><title>Author's
manuscript</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bmjopen-2022-068729.draft_revisions.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><fn-group><fn fn-type="other"><p><bold>Twitter:</bold> @_megankurz</p></fn><fn fn-type="other"><p><bold>Contributors:</bold> BCG-A conducted literature reviews and wrote the first draft of the article. MK, JEM and BN wrote key methodological components of the article and provided critical revisions. LMD, MP, PB, JB, PG, XJH, KK, PTK, TL, MM, RWP, US, MES, EW and BN aided in the methodological development and provided critical revisions to the manuscript. BN conceptualised and secured funding for the study. All authors approved the final draft. We thank members of the Vancouver Area Network of Drug Users, the BC Association of People on Methadone and the Western Aboriginal Harm Reduction Association as well as Dr Sarah Duffy for their early recommendations, which inspired this line of work.</p></fn><fn fn-type="other"><p><bold>Funding:</bold> This study was funded by the National Institutes on Drug Abuse (NIDA grant no. R01DA050629). All authors had full access to the results in the study and took responsibility for the integrity of the data and accuracy of the analysis.</p></fn><fn fn-type="other"><p><bold>Disclaimer:</bold> The funding source was independent of the design of this study and did not have any role during its execution, analyses, interpretation of the data, writing or decision to submit results.</p></fn><fn fn-type="COI-statement"><p><bold>Competing interests:</bold> None declared.</p></fn><fn fn-type="other"><p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn></fn-group><sec sec-type="ethics-statement"><title>Ethics statements</title><sec><title>Patient consent for publication</title><p content-type="ethics-consent-to-publish">Not applicable.</p></sec></sec><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>British Columbia Centre on Substance Use</collab>, <collab>BC Ministry of Health</collab>, <collab>Ministry of Mental Health and Addictions</collab></person-group>. <source>Urine drug testing in patients prescribed opioid agonist treatment&#8212; breakout resource</source>. <year>2021</year>.</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><article-title>Appropriate use of drug testing in clinical addiction medicine</article-title>. <source>J Addict Med</source><year>2017</year>;<volume>11()</volume>:<fpage>1</fpage>&#8211;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000000322</pub-id><pub-id pub-id-type="pmid">28557842</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Center for Addiction and Mental Health</collab></person-group>. <source>Opioid agonist therapy: a synthesis of Canadian guidelines for treating opioid use disorder</source>. <year>2021</year>.</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>British Columbia Centre on Substance Use, B. C. Ministry of Health</collab></person-group>. <source>A guideline for the clinical management of opioid use disorder</source>. <publisher-name>British Columbia Center on Substance Use</publisher-name>, <year>2017</year>.</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Canadian Research Initiative in Substance Misuse</collab></person-group>. <source>CRISM National guideline for the clinical management of opioid use disorder</source>. <publisher-name>Canadian Institutes on Health Research</publisher-name>, <year>2018</year>.</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><article-title>The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update</article-title>. <source>J Addict Med</source><year>2020</year>;<volume>14</volume>:<fpage>1</fpage>&#8211;<lpage>91</lpage>.:<elocation-id>2S</elocation-id>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000000633</pub-id><pub-id pub-id-type="pmid">32511106</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Ling</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Stephenson</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Vasti</surname><given-names>E</given-names></string-name></person-group>. <source>Guidelines for physicians working in California opioid treatment programs</source>. <publisher-name>California Society of Addiction Medicine</publisher-name>, <year>2019</year>.</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jarvis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hurford</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Appropriate use of drug testing in clinical addiction medicine</article-title>. <source>J Addict Med</source><year>2017</year>;<volume>11</volume>:<fpage>163</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000000323</pub-id><pub-id pub-id-type="pmid">28557958</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Substance Abuse and Mental Health Services Administration</collab></person-group>. <source>Clinical drug testing in primary care. Technical assistance publication (TAP) 32</source>. <publisher-name>Substance Abuse and Mental Heath Services Administration</publisher-name>, <year>2012</year>.</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Substance Abuse and Mental Health Services Administration</collab></person-group>. <source>Telehealth for the Treatment of Serious Mental Illness and Substance Use Disorders</source>. <publisher-name>Substance Abuse and Mental Heath Services Administration</publisher-name>, <year>2021</year>.</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Clinical Guidelines on Drug Misuse and Dependence, Update 2017 Independent Expert Working Group</collab></person-group>. <source>Drug misuse and dependence: UK guidelines on clinical management</source>. <publisher-name>Global and Public Health / Population Health / Healthy Behaviours</publisher-name>, <year>2017</year>.</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>National Institute for Health and Care Excellence</collab></person-group>. <source>Opioid dependence | CKS | NICE</source>. <publisher-name>National Institute on Health and Care Excellence</publisher-name>, <year>2022</year>.</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>New South Wales Ministry of Health</collab></person-group>. <source>NSW clinical guidelines: treatment of opioid dependence - 2018</source>. <publisher-name>NSW Ministry of Health</publisher-name>, <year>2018</year>.</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Western Australia Community Pharmacotherapy Program, Community Program for Opioid Pharmacotherapy Management Committee</collab></person-group>. <source>Clinical policies and procedures for the use of methadone and buprenorphine in the treatment of opioid dependence</source>. <publisher-name>Government of Western Australia Alcohol and Drug Authority</publisher-name>, <year>2014</year>.</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Ministry of Health</collab></person-group>. <source>New Zealand practice guidelines for opioid substitution treatment</source>. <year>2014</year>.</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Haute Autorit&#233; de Sant&#233;</collab></person-group>. <source>Strat&#233;gies th&#233;rapeutiques pour les personnes d&#233;pendantes des opiac&#233;s: place des traitements de substitution. Report No.: 07554982 Contract No.: 18</source>. <year>2004</year>.<pub-id pub-id-type="pmid">15617175</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Substance Abuse and Mental Health Services Administration</collab></person-group>. <source>TIP 63: medications for opioid use disorder</source>. <publisher-name>Substance Abuse and Mental Heath Services Administration</publisher-name>, <year>2021</year>.</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Gowing</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dunlop</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <source>National guidelines for medication-assisted treatment of opioid dependence</source>. <publisher-name>Commonwealth of Australia</publisher-name>, <year>2014</year>.</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Waggoner</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Delaney</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Korpi-Steiner</surname><given-names>NL</given-names></string-name></person-group>. <article-title>Comparative analyses of three point-of-care urine drug test devices' performance characteristics for use in ambulatory clinic settings</article-title>. <source>J Appl Lab Med</source><year>2022</year>;<volume>7</volume>:<fpage>495</fpage>&#8211;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1093/jalm/jfab095</pub-id><pub-id pub-id-type="pmid">34597363</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Manchikanti</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Malla</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wargo</surname><given-names>BW</given-names></string-name></person-group>. <article-title>Comparative evaluation of the accuracy of immunoassay with liquid chromatography Tandem mass Spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients</article-title>. <source>Pain Phys</source><year>2011</year>;<volume>3;14</volume>:<fpage>175</fpage>&#8211;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.36076/ppj.2011/14/175</pub-id><pub-id pub-id-type="pmid">21412372</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bertholf</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Reisfield</surname><given-names>GM</given-names></string-name></person-group>. <article-title>Predictive value of positive drug screening results in an urban outpatient population</article-title>. <source>J Anal Toxicol</source><year>2016</year>;<volume>40</volume>:<fpage>726</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1093/jat/bkw088</pub-id><pub-id pub-id-type="pmid">27550994</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Snyder</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Fantz</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Melanson</surname><given-names>S</given-names></string-name></person-group>. <article-title>Immunoassay-based drug tests are inadequately sensitive for medication compliance monitoring in patients treated for chronic pain</article-title>. <source>Pain Physician</source><year>2017</year>;<volume>20</volume>:<fpage>SE1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28226337</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pergolizzi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pappagallo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stauffer</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The role of urine drug testing for patients on opioid therapy</article-title>. <source>Pain Practice</source><year>2010</year>;<volume>10</volume>:<fpage>497</fpage>&#8211;<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1111/j.1533-2500.2010.00375.x</pub-id><pub-id pub-id-type="pmid">20412503</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>P</given-names></string-name></person-group>. <article-title>Point-of-care drug of abuse testing in the opioid epidemic</article-title>. <source>Arch Pathol Lab Med</source><year>2020</year>;<volume>144</volume>:<fpage>1325</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.5858/arpa.2020-0055-RA</pub-id><pub-id pub-id-type="pmid">32579399</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kale</surname><given-names>N</given-names></string-name></person-group>. <article-title>Urine drug tests: ordering and interpreting results</article-title>. <source>Am Fam Physician</source><year>2019</year>;<volume>99</volume>:<fpage>33</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30600984</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Biggar</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Papamihali</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Leclerc</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Towards cross-Canada monitoring of the unregulated Street drug supply</article-title>. <source>BMC Public Health</source><year>2021</year>;<volume>21</volume>:<elocation-id>1678</elocation-id>. <pub-id pub-id-type="doi">10.1186/s12889-021-11757-x</pub-id><pub-id pub-id-type="pmid">34525994</pub-id><pub-id pub-id-type="pmcid">PMC8441944</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amlani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>McKee</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Khamis</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Why the FUSS (fentanyl urine screen study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada</article-title>. <source>Harm Reduct J</source><year>2015</year>;<volume>12</volume>:<elocation-id>54</elocation-id>. <pub-id pub-id-type="doi">10.1186/s12954-015-0088-4</pub-id><pub-id pub-id-type="pmid">26577516</pub-id><pub-id pub-id-type="pmcid">PMC4650899</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Payer</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Maloney-Hall</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Adulterants, Contaminants and Co-occurring substances in drugs on the illegal market in Canada: an analysis of data from drug seizures, drug checking and urine toxicology. Ottawa, Ontario</article-title>. <year>2020</year>.</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>College of Physicians and Surgeons of British Columbia</collab></person-group>. <article-title>Methadone maintenance program: clinical practice guideline 2015</article-title>. <comment>n.d.</comment><comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Publications/Epid/Other/02_CPSBC-Methadone_Maintenance_Program_Clinical%20_Practice_Guideline.pdf">http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Publications/Epid/Other/02_CPSBC-Methadone_Maintenance_Program_Clinical%20_Practice_Guideline.pdf</uri></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carroll</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>RD</given-names></string-name></person-group>. <article-title>The role of behavioral interventions in buprenorphine maintenance treatment: A review</article-title>. <source>Am J Psychiatry</source><year>2017</year>;<volume>174</volume>:<fpage>738</fpage>&#8211;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2016.16070792</pub-id><pub-id pub-id-type="pmid">27978771</pub-id><pub-id pub-id-type="pmcid">PMC5474206</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amato</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Minozzi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Davoli</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence</article-title>. <source>Cochrane Database Syst Rev</source><year>2011</year>. <pub-id pub-id-type="doi">10.1002/14651858.CD004147.pub4</pub-id><pub-id pub-id-type="pmid">21975742</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baxter</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>DeShields</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Safe methadone induction and stabilization</article-title>. <source>J Addict Med</source><year>2013</year>;<volume>7</volume>:<fpage>377</fpage>&#8211;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1097/01.ADM.0000435321.39251.d7</pub-id><pub-id pub-id-type="pmid">24189172</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Korownyk</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Perry</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ton</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Opioid use disorder in primary care: PEER umbrella systematic review of systematic reviews</article-title>. <source>Can Fam Physician</source><year>2019</year>;<volume>65</volume>:<fpage>e194</fpage>&#8211;<lpage>206</lpage>.<pub-id pub-id-type="pmid">31088885</pub-id><pub-id pub-id-type="pmcid">PMC6516704</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dupouy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>M&#233;mier</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Catala</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Does urine drug abuse screening help for managing patients? A systematic review</article-title>. <source>Drug Alcohol Depend</source><year>2014</year>;<volume>136</volume>:<fpage>11</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2013.12.009</pub-id><pub-id pub-id-type="pmid">24417964</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McEachern</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Adye-White</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Priest</surname><given-names>KC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Lacking evidence for the association between frequent urine drug screening and health outcomes of persons on opioid agonist therapy</article-title>. <source>Int J Drug Policy</source><year>2019</year>;<volume>64</volume>:<fpage>30</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugpo.2018.08.006</pub-id><pub-id pub-id-type="pmid">30551003</pub-id><pub-id pub-id-type="pmcid">PMC6500449</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nielsen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Larance</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Opioid agonist treatment for pharmaceutical opioid dependent people</article-title>. <source>Cochrane Database Syst Rev</source><year>2016</year>:<elocation-id>CD011117</elocation-id>. <pub-id pub-id-type="doi">10.1002/14651858.CD011117.pub2</pub-id><pub-id pub-id-type="pmid">27157143</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Wells</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Felipe</surname><given-names>E</given-names></string-name></person-group>. <source>Drug testing for patients with substance use disorder: clinical effectiveness and guidelines</source>. <publisher-name>Canadian Agency for Drugs and Technologies in Health (CADTH))</publisher-name>, <year>2017</year>.</mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bagley</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Winter</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Opioid and cocaine use among primary care patients on buprenorphine-self-report and urine drug tests</article-title>. <source>Drug Alcohol Depend</source><year>2018</year>;<volume>192</volume>:<fpage>245</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.08.010</pub-id><pub-id pub-id-type="pmid">30290291</pub-id><pub-id pub-id-type="pmcid">PMC6291245</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Durand</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Keenan</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Boland</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Consensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: a national Delphi study</article-title>. <source>Int J Drug Policy</source><year>2022</year>;<volume>106</volume>:<elocation-id>S0955-3959(22)00187-6</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.drugpo.2022.103768</pub-id><pub-id pub-id-type="pmcid">PMC9212711</pub-id><pub-id pub-id-type="pmid">35738029</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>DiBenedetto</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Wawrzyniak</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Schatman</surname><given-names>ME</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Increased frequency of urine drug testing in chronic opioid therapy: rationale for strategies for enhancing patient adherence and safety</article-title><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JPR.S213536</pub-id><pub-id pub-id-type="pmcid">PMC6661994</pub-id><pub-id pub-id-type="pmid">31413622</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Argoff</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Alford</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Fudin</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Rational urine drug monitoring in patients receiving opioids for chronic pain: consensus recommendations</article-title>. <source>Pain Med</source><year>2018</year>;<volume>19</volume>:<fpage>97</fpage>&#8211;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1093/pm/pnx285</pub-id><pub-id pub-id-type="pmid">29206984</pub-id><pub-id pub-id-type="pmcid">PMC6516588</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lagisetty</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Klasa</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bush</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Primary care models for treating opioid use disorders: what actually works? A systematic review</article-title>. <source>PLoS One</source><year>2017</year>;<volume>12</volume>:<elocation-id>e0186315</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0186315</pub-id><pub-id pub-id-type="pmid">29040331</pub-id><pub-id pub-id-type="pmcid">PMC5645096</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>BC Coroners Service &amp; BC Ministry of Health</collab></person-group>. <article-title>Preventing pharmaceutical opioid-associated mortality in British Columbia: A review of prescribed opioid overdose deaths, 2009-2013</article-title>. <year>2017</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www2.gov.bc.ca/assets/gov/birth-adoption-death-marriage-and-divorce/deaths/coroners-service/statistical/pharmaceutical-opioid-mortality.pdf">https://www2.gov.bc.ca/assets/gov/birth-adoption-death-marriage-and-divorce/deaths/coroners-service/statistical/pharmaceutical-opioid-mortality.pdf</uri></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>BC Coroners&#160;Service</collab></person-group>. <article-title>BC Coroners service death review panel: a review of illicit drug overdoses</article-title>. <year>2018</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www2.gov.bc.ca/assets/gov/birth-adoption-death-marriage-and-divorce/deaths/coroners-service/death-review-panel/bccs_illicit_drug_overdose_drp_report.pdf">https://www2.gov.bc.ca/assets/gov/birth-adoption-death-marriage-and-divorce/deaths/coroners-service/death-review-panel/bccs_illicit_drug_overdose_drp_report.pdf</uri></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Compton</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Methadone-involved overdose deaths in the US before and after Federal policy changes expanding take-home methadone doses from opioid treatment programs</article-title>. <source>JAMA Psychiatry</source><year>2022</year>;<volume>79</volume>:<fpage>932</fpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2022.1776</pub-id><pub-id pub-id-type="pmid">35830198</pub-id><pub-id pub-id-type="pmcid">PMC9280608</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nosyk</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Anglin</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Brissette</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A call for evidence-based medical treatment of opioid dependence in the United States and Canada</article-title>. <source>Health Affairs</source><year>2013</year>;<volume>32</volume>:<fpage>1462</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1377/hlthaff.2012.0846</pub-id><pub-id pub-id-type="pmid">23918492</pub-id><pub-id pub-id-type="pmcid">PMC4570728</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kenney</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Conti</surname><given-names>MT</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Expected and actual fentanyl exposure among persons seeking opioid withdrawal management</article-title>. <source>J Subst Abuse Treat</source><year>2018</year>;<volume>86</volume>:<fpage>65</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsat.2018.01.005</pub-id><pub-id pub-id-type="pmid">29415853</pub-id><pub-id pub-id-type="pmcid">PMC5808984</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arfken</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Suchanek</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Greenwald</surname><given-names>MK</given-names></string-name></person-group>. <article-title>Characterizing fentanyl use in methadone-maintained clients</article-title>. <source>J Subst Abuse Treat</source><year>2017</year>;<volume>75</volume>:<fpage>17</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsat.2017.01.004</pub-id><pub-id pub-id-type="pmid">28237050</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karamouzian</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Papamihali</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Known fentanyl use among clients of harm reduction sites in British Columbia, Canada</article-title>. <source>Int J Drug Policy</source><year>2020</year>;<volume>77</volume>:<elocation-id>S0955-3959(20)30006-2</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.drugpo.2020.102665</pub-id><pub-id pub-id-type="pmid">31962283</pub-id></mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Government of British Columbia</collab></person-group>. <source>Responding to British Columbia&#8217;s drug poisoning crisis</source>. <year>2021</year>.</mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Whitley</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>LaRue</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fernandez</surname><given-names>SA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Analysis of urine drug test results from substance use disorder treatment practices and overdose mortality rates, 2013-2020</article-title>. <source>JAMA Netw Open</source><year>2022</year>;<volume>5</volume>:<elocation-id>e2215425</elocation-id>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.15425</pub-id><pub-id pub-id-type="pmid">35657623</pub-id><pub-id pub-id-type="pmcid">PMC9166618</pub-id></mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>United States Drug Enforcement Administration</collab></person-group>. <source>2020 National drug threat assessment. US Department of Justice</source>. <year>2021</year>.</mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ickowicz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kerr</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Grant</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Increasing preference for fentanyl among a cohort of people who use opioids in Vancouver, Canada, 2017-2018</article-title>. <source>Subst Abus</source><year>2022</year>;<volume>43</volume>:<fpage>458</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1080/08897077.2021.1946892</pub-id><pub-id pub-id-type="pmid">34283705</pub-id><pub-id pub-id-type="pmcid">PMC8881085</pub-id></mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morales</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Glick</surname><given-names>JL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities</article-title>. <source>Drug Alcohol Depend</source><year>2019</year>;<volume>204</volume>:<elocation-id>107547</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.107547</pub-id><pub-id pub-id-type="pmid">31536877</pub-id></mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Socias</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Grant</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hayashi</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The use of diverted pharmaceutical opioids is associated with reduced risk of fentanyl exposure among people using unregulated drugs in Vancouver, Canada</article-title>. <source>Drug Alcohol Depend</source><year>2021</year>;<volume>228</volume>:<elocation-id>109109</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.109109</pub-id><pub-id pub-id-type="pmid">34601278</pub-id><pub-id pub-id-type="pmcid">PMC8595770</pub-id></mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bardwell</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ivsins</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Soc&#237;as</surname><given-names>ME</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Examining factors that shape use and access to diverted prescription opioids during an overdose crisis: A qualitative study in Vancouver, Canada</article-title>. <source>J Subst Abuse Treat</source><year>2021</year>;<volume>130</volume>:<elocation-id>108418</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.jsat.2021.108418</pub-id><pub-id pub-id-type="pmid">34118706</pub-id></mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bazazi</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Yokell</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>JJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Illicit use of buprenorphine/naloxone among injecting and Noninjecting opioid users</article-title>. <source>J Addict Med</source><year>2011</year>;<volume>5</volume>:<fpage>175</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0b013e3182034e31</pub-id><pub-id pub-id-type="pmid">21844833</pub-id><pub-id pub-id-type="pmcid">PMC3157053</pub-id></mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frank</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mateu-Gelabert</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Perlman</surname><given-names>DC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>It&#8217;s like &#8216;liquid handcuffs: the effects of take-home dosing policies on methadone maintenance treatment (MMT) patients&#8217; lives</article-title>. <source>Harm Reduct J</source><year>2021</year>;<volume>18</volume>:<elocation-id>88</elocation-id>. <pub-id pub-id-type="doi">10.1186/s12954-021-00535-y</pub-id><pub-id pub-id-type="pmid">34391436</pub-id><pub-id pub-id-type="pmcid">PMC8364307</pub-id></mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Drainoni</surname><given-names>M-L</given-names></string-name>, <string-name name-style="western"><surname>Farrell</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sorensen-Alawad</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Patient perspectives of an integrated program of medical care and substance use treatment</article-title>. <source>AIDS Patient Care and STDs</source><year>2014</year>;<volume>28</volume>:<fpage>71</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1089/apc.2013.0179</pub-id><pub-id pub-id-type="pmid">24428768</pub-id><pub-id pub-id-type="pmcid">PMC3926137</pub-id></mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tofighi</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Chemi</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Patient barriers and Facilitators to medications for opioid use disorder in primary care: an in-depth qualitative survey on buprenorphine and extended-release Naltrexone</article-title>. <source>Substance Use &amp; Misuse</source><year>2019</year>;<volume>54</volume>:<fpage>2409</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1080/10826084.2019.1653324</pub-id><pub-id pub-id-type="pmid">31429351</pub-id><pub-id pub-id-type="pmcid">PMC6883164</pub-id></mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Olding</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hayashi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Pearce</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Developing a patient-reported experience questionnaire with and for people who use drugs: A community engagement process in Vancouver&#8217;s downtown Eastside</article-title>. <source>Int J Drug Policy</source><year>2018</year>;<volume>59</volume>:<fpage>16</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugpo.2018.06.003</pub-id><pub-id pub-id-type="pmid">29966804</pub-id></mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farnum</surname><given-names>SO</given-names></string-name>, <string-name name-style="western"><surname>Makarenko</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Madden</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine</article-title>. <source>Addiction</source><year>2021</year>;<volume>116</volume>:<fpage>83</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1111/add.15115</pub-id><pub-id pub-id-type="pmid">32428276</pub-id><pub-id pub-id-type="pmcid">PMC7674222</pub-id></mixed-citation></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Penney</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>McLaren</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wilkie</surname><given-names>T</given-names></string-name></person-group>. <article-title>Urine drug screening in a Forensic mental health population: frequency and clinical utility in risk management</article-title>. <source>J Forensic Psych Psychol</source><year>2021</year>;<volume>32</volume>:<fpage>431</fpage>&#8211;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1080/14789949.2020.1859590</pub-id></mixed-citation></ref><ref id="R64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aronowitz</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Engel-Rebitzer</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dolan</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives</article-title>. <source>Harm Reduct J</source><year>2021</year>;<volume>18</volume>:<elocation-id>119</elocation-id>. <pub-id pub-id-type="doi">10.1186/s12954-021-00572-7</pub-id><pub-id pub-id-type="pmid">34823538</pub-id><pub-id pub-id-type="pmcid">PMC8614631</pub-id></mixed-citation></ref><ref id="R65"><label>65</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>British Columbia Ministry of Health [creator]</collab></person-group>. <article-title>Pharmanet. British Columbia Ministry of health [publisher]. Data Extract</article-title>. <year>MOH, 2021</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.health.gov.bc.ca/data">http://www.health.gov.bc.ca/data</uri></mixed-citation></ref><ref id="R66"><label>66</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>British Columbia Ministry of Health [creator]</collab></person-group>. <article-title>Discharge abstract database (hospital separations). British Columbia Ministry of health [publisher]. Data Extract</article-title>. <year>MOH, 2021</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.health.gov.bc.ca/data">http://www.health.gov.bc.ca/data</uri></mixed-citation></ref><ref id="R67"><label>67</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>British Columbia Ministry of Health [creator]</collab></person-group>. <article-title>Medical services plan (MSP) payment information file. British Columbia Ministry of health [publisher]. Data Extract</article-title>. <year>MOH, 2021</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.health.gov.bc.ca/data">http://www.health.gov.bc.ca/data</uri></mixed-citation></ref><ref id="R68"><label>68</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>BC Vital Statistics Agency [creator]</collab></person-group>. <article-title>Vital Statistics deaths. British Columbia Ministry of health [publisher]. Data Extract</article-title>. <year>MOH, 2021</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.health.gov.bc.ca/data">http://www.health.gov.bc.ca/data</uri></mixed-citation></ref><ref id="R69"><label>69</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Ministry of Public Safety and Solicitor General (PSSG) [creator]</collab></person-group>. <article-title>BC corrections Dataset. British Columbia Ministry of health [publisher]. Data Extract</article-title>. <year>MOH, 2021</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.health.gov.bc.ca/data">http://www.health.gov.bc.ca/data</uri></mixed-citation></ref><ref id="R70"><label>70</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Perinatal Services BC [creator]</collab></person-group>. <article-title>British Columbia perinatal data Registry. British Columbia Ministry of health [publisher]. Data Extract</article-title>. <year>MOH, 2021</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.health.gov.bc.ca/data">http://www.health.gov.bc.ca/data</uri></mixed-citation></ref><ref id="R71"><label>71</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>British Columbia Ministry of Health [creator]</collab></person-group>. <article-title>National ambulatory care reporting system (NACRS). British Columbia Ministry of health [publisher]. Data Extract</article-title>. <year>MOH, 2021</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.health.gov.bc.ca/data">http://www.health.gov.bc.ca/data</uri></mixed-citation></ref><ref id="R72"><label>72</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>British Columbia Ministry of Social Development and Poverty Reduction [creator]</collab></person-group>. <article-title>Social development and poverty reduction database (SDPR). British Columbia Ministry of health [publisher]. Data Extract</article-title>. <year>MOH, 2021</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.health.gov.bc.ca/data">http://www.health.gov.bc.ca/data</uri></mixed-citation></ref><ref id="R73"><label>73</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Government of British Columbia</collab></person-group>. <article-title>Personal Health Identification</article-title>. <comment>n.d.</comment><comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/msp/bc-residents/personal-health-identification">https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/msp/bc-residents/personal-health-identification</uri></mixed-citation></ref><ref id="R74"><label>74</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Government of British Columbia</collab></person-group>. <article-title>Alternative Payments Program</article-title>. <year>2018</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/physician-compensation/alternative-payments-program">https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/physician-compensation/alternative-payments-program</uri></mixed-citation></ref><ref id="R75"><label>75</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Government of Canada</collab></person-group>. <article-title>Health Canada to propose regulatory change to enable consideration of applications under the special access programme to facilitate treatment of chronic Relapsing opioid dependence</article-title>. <year>2016</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canada.ca/en/health-canada/news/2016/05/health-canada-to-propose-regulatory-change-to-enable-consideration-of-applications-under-the-special-access-programme-to-facilitate-treatment-of-chronic-relapsing-opioid-dependence.html">https://www.canada.ca/en/health-canada/news/2016/05/health-canada-to-propose-regulatory-change-to-enable-consideration-of-applications-under-the-special-access-programme-to-facilitate-treatment-of-chronic-relapsing-opioid-dependence.html</uri></mixed-citation></ref><ref id="R76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rubin</surname><given-names>DB</given-names></string-name></person-group>. <article-title>Estimating causal effects of treatments in randomized and Nonrandomized studies</article-title>. <source>Journal of Educational Psychology</source><year>1974</year>;<volume>66</volume>:<fpage>688</fpage>&#8211;<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1037/h0037350</pub-id></mixed-citation></ref><ref id="R77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Caniglia</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Sabin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Robins</surname><given-names>JM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>When to monitor Cd4 cell count and HIV RNA to reduce mortality and AIDS-defining illness in Virologically suppressed HIV-positive persons on antiretroviral therapy in high-income countries: A prospective observational study</article-title>. <source>J Acquir Immune Defic Syndr</source><year>2016</year>;<volume>72</volume>:<fpage>214</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0000000000000956</pub-id><pub-id pub-id-type="pmid">26895294</pub-id><pub-id pub-id-type="pmcid">PMC4866894</pub-id></mixed-citation></ref><ref id="R78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cain</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Robins</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Lanoy</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data</article-title>. <source>Int J Biostat</source><year>2010</year>;<volume>6</volume>:<elocation-id>18</elocation-id>. <pub-id pub-id-type="doi">10.2202/1557-4679.1212</pub-id><pub-id pub-id-type="pmcid">PMC3406513</pub-id><pub-id pub-id-type="pmid">21972433</pub-id></mixed-citation></ref><ref id="R79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maringe</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Benitez Majano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Exarchakou</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Reflection on modern methods: trial Emulation in the presence of immortal-time bias. assessing the benefit of major surgery for elderly lung cancer patients using observational data</article-title>. <source>Int J Epidemiol</source><year>2020</year>;<volume>49</volume>:<fpage>1719</fpage>&#8211;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1093/ije/dyaa057</pub-id><pub-id pub-id-type="pmid">32386426</pub-id><pub-id pub-id-type="pmcid">PMC7823243</pub-id></mixed-citation></ref><ref id="R80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Lyu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></string-name></person-group>. <article-title>Versatility of the clone-Censor-weight approach: response to "trial Emulation in the presence of immortal-time bias</article-title><source>Int J Epidemiol</source><year>2021</year>;<volume>50</volume>:<fpage>694</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1093/ije/dyaa223</pub-id><pub-id pub-id-type="pmid">33349843</pub-id></mixed-citation></ref><ref id="R81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nosyk</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Guh</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Bansback</surname><given-names>NJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cost-effectiveness of Diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment</article-title>. <source>CMAJ</source><year>2012</year>;<volume>184</volume>:<fpage>E317</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1503/cmaj.110669</pub-id><pub-id pub-id-type="pmid">22410375</pub-id><pub-id pub-id-type="pmcid">PMC3314060</pub-id></mixed-citation></ref><ref id="R82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hern&#225;n</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Lanoy</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Costagliola</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Comparison of dynamic treatment regimes via inverse probability weighting</article-title>. <source>Basic Clin Pharmacol Toxicol</source><year>2006</year>;<volume>98</volume>:<fpage>237</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1111/j.1742-7843.2006.pto_329.x</pub-id><pub-id pub-id-type="pmid">16611197</pub-id></mixed-citation></ref><ref id="R83"><label>83</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>EW</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Amato</surname><given-names>DA</given-names></string-name>, <etal>et al</etal></person-group>. <part-title>Cox-type regression analysis for large numbers of small groups of correlated failure time observations</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Klein</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Goel</surname><given-names>PK</given-names></string-name></person-group>, eds. <source>Survival analysis: state of the art</source>. <publisher-loc>Dordrecht</publisher-loc>: <publisher-name>Springer Netherlands</publisher-name>, <year>1992</year>: <fpage>237</fpage>&#8211;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1007/978-94-015-7983-4</pub-id></mixed-citation></ref><ref id="R84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kurz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Min</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Dale</surname><given-names>LM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada</article-title>. <source>J Subst Abuse Treat</source><year>2022</year>;<volume>133</volume>:<elocation-id>108647</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.jsat.2021.108647</pub-id><pub-id pub-id-type="pmid">34740484</pub-id><pub-id pub-id-type="pmcid">PMC9833672</pub-id></mixed-citation></ref><ref id="R85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>VanderWeele</surname><given-names>TJ</given-names></string-name></person-group>. <article-title>Principles of Confounder selection</article-title>. <source>Eur J Epidemiol</source><year>2019</year>;<volume>34</volume>:<fpage>211</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s10654-019-00494-6</pub-id><pub-id pub-id-type="pmid">30840181</pub-id><pub-id pub-id-type="pmcid">PMC6447501</pub-id></mixed-citation></ref><ref id="R86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Piske</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Thomson</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Krebs</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada</article-title>. <source>BMJ Open</source><year>2020</year>;<volume>10</volume>:<elocation-id>e036102</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2019-036102</pub-id><pub-id pub-id-type="pmcid">PMC7482450</pub-id><pub-id pub-id-type="pmid">32912944</pub-id></mixed-citation></ref><ref id="R87"><label>87</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Provincial Health Services Authority</collab></person-group>. <source>Identifying determinants for hospitalization based on healthcare utilization records</source>. <year>2008</year>.</mixed-citation></ref><ref id="R88"><label>88</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Canadian Institutes of Health Research</collab></person-group>. <source>Tri-Council policy statement: ethical conduct for research involving humans</source>. <year>2018</year>.</mixed-citation></ref><ref id="R89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>von Elm</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Egger</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>J Clin Epidemiol</source><year>2008</year>;<volume>61</volume>:<fpage>344</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jclinepi.2007.11.008</pub-id><pub-id pub-id-type="pmid">18313558</pub-id></mixed-citation></ref><ref id="R90"><label>90</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <source>World health organization model list of essential medicines for children, 8th list, 2021</source>. <year>2021</year>. <pub-id pub-id-type="doi">10.1530/ey.19.13.1</pub-id></mixed-citation></ref><ref id="R91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sordo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Barrio</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bravo</surname><given-names>MJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies</article-title>. <source>BMJ</source><year>2017</year>;<volume>357</volume>:<elocation-id>j1550</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmj.j1550</pub-id><pub-id pub-id-type="pmid">28446428</pub-id><pub-id pub-id-type="pmcid">PMC5421454</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>